Effects of 1-H-indole-3-glyoxamide (A-002) on concentration of secretory phospholipase A2 (PLASMA study): a phase II double-blind, randomised, placebo-controlled trial.
about
Phospholipase A2 enzymes: physical structure, biological function, disease implication, chemical inhibition, and therapeutic interventionAdmission lipoprotein-associated phospholipase A2 activity is not associated with long-term clinical outcomes after ST-segment elevation myocardial infarction.Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies.Varespladib methyl in cardiovascular disease.Anti-inflammatory therapies for cardiovascular diseaseRandomized trial of an inhibitor of secretory phospholipase A2 on atherogenic lipoprotein subclasses in statin-treated patients with coronary heart disease.Ex vivo effect of varespladib on secretory phospholipase A2 alveolar activity in infants with ARDSEmerging drugs for hyperlipidemia.Group V phospholipase A2 in bone marrow-derived myeloid cells and bronchial epithelial cells promotes bacterial clearance after Escherichia coli pneumonia.Biallelic mutations in PLA2G5, encoding group V phospholipase A2, cause benign fleck retinaPrognostic utility of secretory phospholipase A(2) in patients with stable coronary artery disease.Inflammation-associated changes in lipid composition and the organization of the erythrocyte membrane.Modulation of oxidative stress, inflammation, and atherosclerosis by lipoprotein-associated phospholipase A2Lymphoid tissue phospholipase A2 group IID resolves contact hypersensitivity by driving antiinflammatory lipid mediatorsSecretory phospholipase A(2)-IIA and cardiovascular disease: a mendelian randomization study.Update on patented cholesterol absorption inhibitors.Residual risk for secondary ischemic events in patients with atherothrombotic disease: opportunity for future improvements in patient care.Cardiovascular disease is preventable among women.Diabetic dyslipidemia: extending the target beyond LDL cholesterol.Emerging drugs for coronary artery disease. From past achievements and current needs to clinical promises.Secreted phospholipase A2, lipoprotein hydrolysis, and atherosclerosis: integration with lipidomicsDiscontinued drugs in 2012: cardiovascular drugs.The role of inflammatory biomarkers in developing targeted cardiovascular therapies: lessons from the cardiovascular inflammation reduction trials.Immune-mediated mechanisms of atherosclerosis and implications for the clinic.Matrix metalloproteinase-2 negatively regulates cardiac secreted phospholipase A2 to modulate inflammation and fever.Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Progress in Small Molecule Drug Development.After FRANCIS: next steps in the clinical evaluation of varespladib methyl.Phospholipase A2 inhibitors in the treatment of atherosclerosis: a new approach moves forward in the clinic.Discovery of novel secretory phospholipase A2 inhibitors using virtual screen.Associations between four types of single-nucleotide polymorphisms in PLA2G7 gene and clinical atherosclerosis: a meta-analysis.
P2860
Q26997377-91459E21-3071-4A7D-AFDB-7FF409942554Q33553503-BE3C181F-514D-45E3-9410-386C8EA37169Q33829154-1E5F978E-9B20-4A29-8015-39DE10FAE2F2Q34135420-22057807-8AA6-489C-966B-B72F00548E1CQ34137872-641E8C8E-9767-4689-A807-2669C908C935Q34150154-417772DE-0A9E-4700-8739-443D16757A0AQ34447842-885684C2-6A4A-4B0F-A3F8-370BB50603B7Q34619115-7D04A77E-9069-4308-AB8C-306CB630C309Q35372227-DF8F9AF4-C01E-4518-9490-3B32F3232DC1Q35603281-710A389E-54D4-4F84-A291-FAA916675632Q35627513-901BD49F-F9E4-49A4-8282-9BE22A77A44DQ36023408-0A12F203-09D8-42A5-B0E2-12FFD8A1089CQ36145180-DFFD60B1-7C43-4B0C-B4B1-24B0E9A9DD16Q36907943-52436147-E18D-4C93-B1A5-77612EF6E637Q37303915-B4EC5695-43FA-4B5E-AD00-CFB881541B7AQ37529796-58801B64-4547-4240-A90E-44FB2A254637Q37679209-67BBB161-A8C8-4CF9-A1AB-4396903E746EQ37688153-B330DC92-C3A8-4CCF-BA16-F87667A7CE3FQ37757979-F49CA658-B346-4A90-A094-148BC59A61A7Q37827882-4240534A-FAD1-4B24-8978-2DD372CE57CDQ37858911-C5FFFA50-7471-44A9-A573-449F7642086CQ38132832-9BEB825F-A96D-4AA9-AEF3-EB8126837F04Q38593722-882F474E-70E8-471E-9093-7BD503D111B7Q38851472-25522622-5B2E-4882-948C-57280FF337EAQ38893588-136900C7-D81B-4BDF-B0BF-07EAA5DD1258Q38974307-FEBE070D-01EB-466E-A91B-B36B95223B21Q39803214-B5DC5B6F-DE49-4864-AEB9-2592EE05AFDEQ43289695-A1C16D07-3192-490F-9665-1BC2057F5B87Q46921634-C10D62C7-7F80-4350-8776-726F7B935730Q49475562-65E51B2E-4F51-4603-835C-4E8C85AC167F
P2860
Effects of 1-H-indole-3-glyoxamide (A-002) on concentration of secretory phospholipase A2 (PLASMA study): a phase II double-blind, randomised, placebo-controlled trial.
description
2009 nî lūn-bûn
@nan
2009 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Effects of 1-H-indole-3-glyoxa ...... sed, placebo-controlled trial.
@ast
Effects of 1-H-indole-3-glyoxa ...... sed, placebo-controlled trial.
@en
Effects of 1-H-indole-3-glyoxa ...... sed, placebo-controlled trial.
@nl
type
label
Effects of 1-H-indole-3-glyoxa ...... sed, placebo-controlled trial.
@ast
Effects of 1-H-indole-3-glyoxa ...... sed, placebo-controlled trial.
@en
Effects of 1-H-indole-3-glyoxa ...... sed, placebo-controlled trial.
@nl
prefLabel
Effects of 1-H-indole-3-glyoxa ...... sed, placebo-controlled trial.
@ast
Effects of 1-H-indole-3-glyoxa ...... sed, placebo-controlled trial.
@en
Effects of 1-H-indole-3-glyoxa ...... sed, placebo-controlled trial.
@nl
P2093
P1433
P1476
Effects of 1-H-indole-3-glyoxa ...... sed, placebo-controlled trial.
@en
P2093
Colin Hislop
Daniel McConnell
David D Waters
Michael Elliott
PLASMA Investigators
Robert S Rosenson
Yuri Stasiv
P304
P356
10.1016/S0140-6736(09)60403-7
P407
P577
2009-02-01T00:00:00Z